49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03684564 (ClinicalTrials.gov) | September 2020 | 13/8/2018 | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open Label, Phase II/III, Non-inferiority Trial | Antiphospholipid Syndrome;Systemic Lupus Erythematosus;Stroke;Ischemic Stroke;Brain Ischemia | Drug: Rivaroxaban;Drug: Warfarin | University College, London | Arthritis Research UK;King's College London;University College London Hospitals;Hammersmith Hospitals NHS Trust;Guy's and St Thomas' NHS Foundation Trust;Barts & The London NHS Trust;King's College Hospital NHS Trust;Manchester University NHS Foundation Trust;Barking, Havering and Redbridge University Hospitals NHS Trust;St George's University Hospitals NHS Foundation Trust | Not yet recruiting | 18 Years | N/A | All | 140 | Phase 2/Phase 3 | NULL |
| 2 | EUCTR2018-001735-49-GB (EUCTR) | 01/07/2019 | 22/01/2019 | RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome | Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial - RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome | Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Rivaroxaban Product Name: Rivaroxaban INN or Proposed INN: Rivaroxaban Other descriptive name: Trade Name Xarelto Trade Name: Warfarin Sodium Product Name: Warfarin Sodium INN or Proposed INN: Warfarin sodium | University College London | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 2;Phase 3 | United Kingdom | ||
| 3 | EUCTR2012-002345-38-GB (EUCTR) | 30/10/2012 | 08/10/2012 | Comparison of rivaroxaban (Xarelto®; Bayer HealthCare), fixed-dose oral anticoagulant (blood thinner), versus warfarin in patients with antiphospholipid syndrome (called APS), with or without 'lupus' (systemic lupus erythematosus) | A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. - Rivaroxaban in Antiphospholipid Syndrome (RAPS) | Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE). MedDRA version: 14.1;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Xarelto Product Name: Rivaroxaban INN or Proposed INN: Rivaroxaban Other descriptive name: Trade name Xarelto Trade Name: The generic name is warfarin and many producers will be involved Product Name: Warfarin INN or Proposed INN: Warfarin | University College London | NULL | Not Recruiting | Female: yes Male: yes | 156 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom |